The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients: A Randomized Controlled Trial
Abstract
CONTEXT: Early-onset alcoholism differs from late-onset alcoholism by its association with greater serotonergic abnormality and antisocial behaviors. Thus, individuals with early-onset alcoholism may be responsive to treatment with a selective serotonergic agent. OBJECTIVE: To test the hypothesis that drinking outcomes associated with early vs late-onset alcoholism are differentially improved by the selective 5-HT(3) (serotonin) antagonist ondansetron. DESIGN: Double-blind, randomized, placebo-controlled clinical trial. SETTINGS: University of Texas Health Science Center in Houston (April 1995-June 1998) and University of Texas Health Science Center in San Antonio (July 1998-December 1999). PARTICIPANTS: A total of 321 patients with diagnosed alcoholism (mean age, 40.6 years; 70.5% male; 78.6% white) were enrolled, 271 of whom proceeded to randomization. INTERVENTIONS: After 1 lead-in week of single-blind placebo, patients were randomly assigned to receive 11 weeks of treatment with ondansetron, 1 microg/kg (n = 67), 4 microg/kg (n = 77), or 16 microg/kg (n = 71) twice per day; or identical placebo (n = 56). All patients also participated in weekly standardized group cognitive behavioral therapy. MAIN OUTCOME MEASURES: Self-reported alcohol consumption (drinks per day, drinks per drinking day, percentage of days abstinent, and total days abstinent per study week); and plasma carbohydrate deficient transferrin (CDT) level, an objective and sensitive marker of transient alcohol consumption. RESULTS: Patients with early-onset alcoholism who received ondansetron (1, 4, and 16 microg/kg twice per day) compared with those who were administered placebo, had fewer drinks per day (1.89, 1.56, and 1.87 vs 3.30; P =.03, P =.01, and P =.02, respectively) and drinks per drinking day (4.75, 4.28, and 5.18 vs 6.90; P =.03, P =.004, and P =.03, respectively). Ondansetron, 4 microg/kg twice per day, was superior to placebo in increasing percentage of days abstinent (70.10 vs 50.20; P =.02) and total days abstinent per study week (6.74 vs 5.92; P =.03). Among patients with early-onset alcoholism, there was a significant difference in the mean log CDT ratio between those who received ondansetron (1 and 4 microg/kg twice per day) compared with those who received the placebo (-0.17 and -0.19 vs 0.12; P =.03 and P =.01, respectively). CONCLUSION: Our results suggest that ondansetron (particularly the 4 microg/kg twice per day dosage) is an effective treatment for patients with early-onset alcoholism, presumably by ameliorating an underlying serotonergic abnormality. JAMA. 2000;284:963-971
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Self-efficacy: Toward a unifying theory of behavioral change
Bandura, A. (1978) · Advances in Behaviour Research and Therapy · doi:10.1016/0146-6402(78)90002-4 · Cited by 10,586
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
The Michigan Alcoholism Screening Test: The Quest for a New Diagnostic Instrument
SELZER, M. L. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.127.12.1653 · Cited by 3,438
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Neurogenetic Adaptive Mechanisms in Alcoholism
Cloninger, C. R. (1987) · Science · doi:10.1126/science.2882604 · Cited by 2,234
Self-citationSULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Inheritance of Alcohol Abuse: Cross-Fostering Analysis of Adopted Men
Cloninger, C. R. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780330019001 · Cited by 1,873
Self-citationSocial Class and Mental Illness: A Community Study
(2007) · American Journal of Public Health · doi:10.2105/ajph.97.10.1756 · Cited by 1,840
The Structured Clinical Interview for DSM-III-R (SCID): II. Multisite Test-Retest Reliability
Williams, J. B. W. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080038006 · Cited by 1,618
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503
Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding
Kilpatrick, G. J., Jones, B. J., & Tyers, M. B. (1987) · Nature · doi:10.1038/330746a0 · Cited by 865
Clinical Trials: Design, Conduct and Analysis
Meinert, C. L. (1986) · DigitalGeorgetown (Georgetown University Library) · doi:10.1093/acprof:oso/9780195035681.001.0001 · Cited by 756
Stibler, H. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.12.2029 · Cited by 643
Neural Mechanisms of Drug Reinforcementa
KOOB, G. F. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb25966.x · Cited by 610
Animal Models of Alcoholism: Neurobiology of High Alcohol-Drinking Behavior in Rodents
McBride, W. J., & Li, T.-K. (1998) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v12.i4.40 · Cited by 600
Grant, B. F. (1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.464 · Cited by 511
Testing for baseline balance in clinical trials
Senn, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131703 · Cited by 503
Heinz, A., Jones, D. W., Mazzanti, C., Goldman, D., Ragan, P., Hommer, D., Linnoila, M., & Weinberger, D. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00171-7 · Cited by 466
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Little, K. Y., McLaughlin, D. P., Zhang, L., Livermore, C. S., Dalack, G. W., McFinton, P. R., DelProposto, Z. S., Hill, E., Cassin, B. J., Watson, S. J., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.207 · Cited by 382
Serotonin and alcohol intake, abuse, and dependence: Findings of animal studies
LeMarquand, D., Pihl, R. O., & Benkelfat, C. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91215-7 · Cited by 374
Costall, B., Domeney, A. M., Naylor, R. J., & Tyers, M. B. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11394.x · Cited by 355
Alcohol and Central Serotonin Metabolism in Man
Ballenger, J. C. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780020114013 · Cited by 355
Serotonin and alcohol intake, abuse, and dependence: Clinical evidence
LeMarquand, D., Pihl, R. O., & Benkelfat, C. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90630-0 · Cited by 335
Schuckit, M. A., Mazzanti, C., Smith, T. L., Ahmed, U., Radel, M., Iwata, N., & Goldman, D. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00248-0 · Cited by 250
Age of Alcoholism Onset: I. Relationship to Psychopathology
Buydens-Branchey, L. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810030031004 · Cited by 244
Kranzler, H. R., Burleson, J. A., Brown, J., & Babor, T. F. (1996) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01696.x · Cited by 213
Clinical Efficacy of the 5‐HT3 Antagonist Ondansetron in Alcohol Abuse and Dependence
Sellers, E. M., Toneatto, T., Romach, M. K., Somer, G. R., Sobell, L. C., & Sobell, M. B. (1994) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1994.tb00054.x · Cited by 185
Füs-Aime, M.-L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030029006 · Cited by 184
5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic
Lovinger, D. M. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00054-6 · Cited by 182
Types of alcoholics: concurrent and predictive validity of some common classification schemes
BABOR, T. F., DOLINSKY, Z. S., MEYER, R. E., HESSELBROCK, M., HOFMANN, M., & TENNEN, H. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb01921.x · Cited by 182
Types of Alcoholics, II: Application of an Empirically Derived Typology to Treatment Matching
Litt, M. D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080017003 · Cited by 181
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings
Johnson, B. A., & Ait-Daoud, N. (2000) · Psychopharmacology · doi:10.1007/s002130000371 · Cited by 172
Self-citationFadda, F., GARAU, B., Marchei, F., Colombo, G., & Gessa, G. L. (1991) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045088 · Cited by 150
Serotonin in Early Onset, Male Alcoholics with Violent Behaviour
Virkkunen, M., & Linnoila, M. (1990) · Annals of Medicine · doi:10.3109/07853899009147915 · Cited by 149
Johnson, B. A., Cloninger, C. R., Roache, J. D., Bordnick, P. S., & Ruiz, P. (2000) · American Journal on Addictions · doi:10.1080/10550490050172191 · Cited by 109
Self-citationAssessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.
del Boca, F. D., Kranzler, H., Brown, J., & Korner, P. (1996) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01142.x · Cited by 101
Johnson, B. A., Campling, G. M., Griffiths, P., & Cowen, P. J. (1993) · Psychopharmacology · doi:10.1007/bf02247375 · Cited by 97
Self-citationHodge, C. W., Samson, H. H., Lewis, R. S., & Erickson, H. L. (1993) · Alcohol · doi:10.1016/0741-8329(93)90034-l · Cited by 94
The Central 5-HT3 Receptor in CNS Disorders
Bloom, F. E., & Morales, M. (1998) · Neurochemical Research · doi:10.1023/a:1022486705184 · Cited by 87
Ishiguro, H., Saito, T., Akazawa, S., Mitushio, H., Tada, K., Enomoto, M., Mifune, H., Toru, M., Shibuya, H., & Arinami, T. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04289.x · Cited by 85
Serotonergic Agents and Alcoholism Treatment: Rebirth of the Subtype Concept???An Hypothesis
Johnson, B. A. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb04581.x · Cited by 83
Self-citationTomkins, D. M., Lê, A. D., & Sellers, E. M. (1995) · Psychopharmacology · doi:10.1007/bf02246222 · Cited by 81
Serotonin in Early-Onset Alcoholism
Virkkunen, M. E., & Linnoila, M. (2002) · Springer eBooks · doi:10.1007/0-306-47141-8_10 · Cited by 73
Ondansetron alters human alcohol intoxication
Swift, R. M., Davidson, D., Whelihan, W. M., & Kuznetsov, O. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00432-7 · Cited by 62
Brown, J., Babor, T. F., Litt, M. D., & Kranzler, H. R. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb24695.x · Cited by 52
New Methodologies for Pharmacological Treatment Trials for Alcohol Dependence
Anton, R. F. (1996) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1996.tb01183.x · Cited by 41
5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system
Kilpatrick, G. J., Hagan, R. M., & Gale, J. D. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00063-0 · Cited by 37
Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers
Doty, P., Zacny, J. P., & de Wit, H. (1994) · Behavioural Pharmacology · doi:10.1097/00008877-199408000-00007 · Cited by 28
Huseby, N., Bjordal, E., Nilssen, O., & Barth, T. (1997) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1997.tb04458.x · Cited by 28
Alcohol‐induced reinforcement: Dopamine and 5‐HT3 receptor interactions in animals and humans
Johnson, B. A., & Cowen, P. J. (1993) · Drug Development Research · doi:10.1002/ddr.430300308 · Cited by 27
Self-citationMedications for Alcohol Dependence—New Vistas
Kranzler, H. R. (2000) · JAMA · doi:10.1001/jama.284.8.1016 · Cited by 19
Cited by
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Self-citationNeuropsychology and neuropharmacology of P3a and P3b
Polich, J., & Criado, J. R. (2006) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2005.12.012 · Cited by 741
Should addictive disorders include non-substance-related conditions?
Potenza, M. N. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01591.x · Cited by 663
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
Metadata
- Authors
- Johnson, B. A., Roache, J. D., Javors, M. A., DiClemente, C. C., Cloninger, C. R., Prihoda, T. J., Bordnick, P. S., Ait-Daoud, N., & Hensler, J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-08-23
- Volume
- 284
- Issue
- 8
- Pages
- 963
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2170057342
- Cited by
- 414
- References
- 56
- FWCI
- 17.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.